Search results
Results from the WOW.Com Content Network
Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody, more specifically a PD-1 inhibitor, used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer.
Keytruda, approved for several types of cancer, alone accounts for more than 25% of Merck's (MRK) pharmaceutical sales Animal health and vaccine products remain core growth drivers.
Keytruda sales rose 21% to $6.6 billion as the company was able to increase use of the drug in earlier stage cancers, topping analyst forecasts of $6.5 billion. ... The New Jersey-based drugmaker ...
The failure rate of each of these oral contraceptives is 7%. [1] Some choose to get an injection or a shot in order to prevent pregnancy. This is an option where a medical professional will inject the hormone progestin into a woman's arm or buttocks every 3 months to prevent pregnancy. The failure rate is 4%. [1]
Merck's (MRK) Keytruda is rapidly gaining strength as a key contributor to the company's top line. The Keytruda development program is also progressing well. Merck's Keytruda Picks Up Pace in ...
The United States rate of unintended pregnancies is higher than the world average, and much higher than that in other industrialized nations. [33] Almost half (49%) of U.S. pregnancies are unintended, more than 3 million unintended pregnancies per year. [34] [35] The rate of unintended pregnancy is even higher among the poor. In 1990 about 44% ...
Keytruda has not been approved for the treatment of MSS mCRC. Last month, Merck stopped two Keytruda Phase 3 trials, KEYNOTE-867 and KEYNOTE-630, after underwhelming data .
The replacement fertility rate is 2.1 births per female for most developed countries (in the United Kingdom, for example), but can be as high as 3.5 in undeveloped countries because of higher mortality rates, especially child mortality. [9]